New combo therapy aims to tame deadly immune storm with fewer side effects
Disease control
Recruiting now
This study tests a new treatment for adults with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system attacks the body. The treatment combines a targeted drug (ruxolitinib) with a shorter, milder version of standard therapy to reduce side effects whi…
Phase: PHASE2 • Sponsor: Jerry Lee, MD, MSc, MPhil • Aim: Disease control
Last updated May 08, 2026 12:01 UTC